BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
16.15
-0.10 (-0.62%)
At close: Mar 27, 2026, 4:00 PM EDT
16.00
-0.15 (-0.93%)
After-hours: Mar 27, 2026, 5:58 PM EDT
BioAge Labs Employees
As of December 31, 2025, BioAge Labs had 62 total employees, including 60 full-time and 2 part-time employees. The number of employees decreased by 2 or -3.13% compared to the previous year.
Employees
62
Change (1Y)
-2
Growth (1Y)
-3.13%
Revenue / Employee
$145,081
Profits / Employee
-$1,300,081
Market Cap
716.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 62 | -2 | -3.13% | 60 | 2 |
| Dec 31, 2024 | 64 | 8 | 14.29% | 62 | 2 |
| Jun 30, 2024 | 60 | - | - | 58 | 2 |
| Mar 31, 2024 | 56 | - | - | 54 | 2 |
| Dec 31, 2023 | 56 | - | - | 54 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,788 |
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Alvotech | 1,012 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Collegium Pharmaceutical | 423 |
| Esperion Therapeutics | 294 |
BIOA News
- 2 months ago - BioAge Announces Pricing of Upsized $115.0 Million Public Offering - GlobeNewsWire
- 2 months ago - BioAge Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - GlobeNewsWire
- 2 months ago - BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk - GlobeNewsWire
- 4 months ago - BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - GlobeNewsWire
- 4 months ago - BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 months ago - BioAge Labs to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 6 months ago - HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor - PRNewsWire